Project Grant R21DA058120
Award Date
9/15/24
Completion Date
8/31/26
Dollars Obligated
$267K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded Rebel Medicine Inc. a $591,842 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop an extended-duration injectable local anesthetic formulation as an alternative to opioid-based pain medications. The project aims to demonstrate the safety and efficacy of a proprietary lipophilic bupivacaine oleogel formulation that can provide up to 7 days of sustained pain relief from a single injection, mitigating the...
The National Institute on Drug Abuse (NIDA) awarded a $326,410 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Berkshire Biomedical Corporation in Dallas, TX. The grant will fund a two-phased clinical study to evaluate the feasibility, acceptance, and impact on treatment retention of a hand-held, automated, personalized oral liquid dispensing system (COPA) for delivering take-home methadone to patients with opioid use disorder. The initial single-site pilot...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, is supporting the development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for the treatment of opioid use disorder (OUD). The $2,932,500 award to The Drug Delivery Company, LLC will fund the development of this 6-month buprenorphine implant, building upon the company's prior success with a 6-month bioabsorbable...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to support the clinical development of PF614-MPAR, an opioid product with oral overdose protection. The key objectives of this project are to continue the clinical development of PF614-MPAR, a combination product of a trypsin-activated abuse protection (TAAP) oxycodone prodrug and a trypsin inhibitor...
The National Institute on Drug Abuse (NIDA) awarded a $306,528 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Addinex Technologies, Inc. The grant will fund the development of a medication adherence and monitoring system to support decentralized clinical trials for substance use disorder (SUD). The project aims to adapt Addinex's existing medication management system to provide researchers running SUD clinical trials with a tool for at-home dispensing that...
The National Institute on Drug Abuse (NIDA) awarded a $1,539,426 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Serodopa Therapeutics Inc. to develop a novel intranasal formulation of a naloxone derivative for the reversal of opioid-induced respiratory depression caused by high-potency opioids such as fentanyl. The project aims to complete formulation development, preclinical toxicology and safety testing required to prepare an Investigational New Drug (IND)...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc.'s Human Biomolecular Research Institute in San Diego, CA. The funding supports research to design, synthesize, and test non-opioid drug candidates as potential treatments for opioid use disorder and fentanyl toxicity. Key objectives include characterizing the effects of opioids on human induced pluripotent stem...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded Labsys LLC a $643,948 Project Grant to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The goal is to create a low-cost, pain-free patch that can monitor medication levels in the interstitial fluid and provide real-time insights into the effectiveness of opioid use disorder treatment protocols. In Phase I, Labsys will engineer an...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $598,312 to Addinex Technologies, Inc. to integrate and assess the practicality of a closed-loop medication management system for opioid pain management targeting ambulatory patients with extremity fractures being discharged from the emergency department. The key objectives are to adapt the Addinex system to seamlessly integrate with hospital...
This Project Grant award of $994,004, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to engage adolescents, young adults, parents, providers, pharmacists, and people who use drugs to generate knowledge to guide future overdose prevention interventions tailored for youth. The key objectives are to: 1) explore perceptions of overdose risk, drug supply, and safety precautions among 13-17 and 18-25 year olds through focus...